HEPRONICATE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C28H31N3O6
Molecular Weight	505.5622
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCCCC(COC(=O)C1=CN=CC=C1)(COC(=O)C2=CN=CC=C2)COC(=O)C3=CN=CC=C3

InChI

InChIKey=GUIBJJJLGSYNKE-UHFFFAOYSA-N

InChI=1S/C28H31N3O6/c1-2-3-4-5-12-28(19-35-25(32)22-9-6-13-29-16-22,20-36-26(33)23-10-7-14-30-17-23)21-37-27(34)24-11-8-15-31-18-24/h6-11,13-18H,2-5,12,19-21H2,1H3

HIDE SMILES / InChI

Molecular Formula	C28H31N3O6
Molecular Weight	505.5622
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.nipro-es-pharma.co.jp/product/di/files/tb/HPNC_a_tb_001201.html

Hepronicate is a nicotinic acid derivative, developed and used in Japan under the name Megrin for the treatment of peripheral circulatory disorders. The therapeutic effect of the drug is explained by its vasodilation properties.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
vasoconstriction 30 Target ID: GO:0042310 Sources: https://www.nipro-es-pharma.co.jp/product/di/files/tb/HPNC_a_tb_001201.html	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Raynaud's disease 5 Sources: https://www.nipro-es-pharma.co.jp/product/di/files/tb/HPNC_a_tb_001201.html	Palliative	Approved 8583	MEGRIN Approved Use Peripheral circulatory disorders such as Raynaud's disease, Buerger's disease, arteriosclerosis obliterans; chilblains, frostbite. Launch Date 1971
Buerger's disease 1 Sources: https://www.nipro-es-pharma.co.jp/product/di/files/tb/HPNC_a_tb_001201.html	Palliative	Approved 8583	MEGRIN Approved Use Peripheral circulatory disorders such as Raynaud's disease, Buerger's disease, arteriosclerosis obliterans; chilblains, frostbite. Launch Date 1971
Arteriosclerosis obliterans 7 Sources: https://www.nipro-es-pharma.co.jp/product/di/files/tb/HPNC_a_tb_001201.html	Palliative	Approved 8583	MEGRIN Approved Use Peripheral circulatory disorders such as Raynaud's disease, Buerger's disease, arteriosclerosis obliterans; chilblains, frostbite. Launch Date 1971
Frostbite 1 Sources: https://www.nipro-es-pharma.co.jp/product/di/files/tb/HPNC_a_tb_001201.html	Curative	Approved 8583	MEGRIN Approved Use Peripheral circulatory disorders such as Raynaud's disease, Buerger's disease, arteriosclerosis obliterans; chilblains, frostbite. Launch Date 1971
Chilblains 1 Sources: https://www.nipro-es-pharma.co.jp/product/di/files/tb/HPNC_a_tb_001201.html	Curative	Approved 8583	MEGRIN Approved Use Peripheral circulatory disorders such as Raynaud's disease, Buerger's disease, arteriosclerosis obliterans; chilblains, frostbite. Launch Date 1971

Patents

Sample Use Guides

In Vivo Use Guide

The recommended adult dose is 300-600 mg (3-6 tablets) administered orally three times/day after food.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:01:33 GMT 2025` Edited by `admin` on `Mon Mar 31 18:01:33 GMT 2025`
Record UNII	E4RK86FAVR
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

HEPRONICATE

Official Name

English

MEGRIN

Preferred Name

English

HEPRONICATE [MI]

Common Name

English

2-HEXYL-2-(HYDROXYMETHYL)-1,3-PROPANEDIOL TRINICOTINATE

Systematic Name

English

hepronicate [INN]

Common Name

English

HEPRONICATE [JAN]

Common Name

English

HEPRONICATE [MART.]

Common Name

English

Hepronicate [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C471